138844-81-2

Basic information

• Product Name: Ibandronate sodium
• Synonyms: Ibandronic Acid Sodium Salt;sodium [1-hydroxy-1-(hydroxy-oxido-phosphoryl)-3-(methyl-pentyl-amino) propyl]phosphonic acid;(1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonic acid monosodium salt;Ibandronate Sodium Anhydrous;Bondronat, (1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonic acid sodium;Ibandronate sodium;Bondronat;Ibandronate sodiuM Bondronat
• CAS NO: 138844-81-2
• Molecular Formula: C₁₀H₂₄NO₇P₂*Na
• Molecular Weight: 341.21
• EINECS: 1308068-626-2
• Product Categories: anti-osteoporosis;API
• Mol File: 138844-81-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 587.8 °C at 760 mmHg
• Flash Point: 309.3 °C
• Appearance: white/
• Vapor Pressure: 2.88E-16mmHg at 25°C
• Storage Temp.: 2-8°C
• Solubility: H2O: >10mg/mL
• Merck: 14,4873
• CAS DataBase Reference: Ibandronate sodium(CAS DataBase Reference)
• NIST Chemistry Reference: Ibandronate sodium(138844-81-2)
• EPA Substance Registry System: Ibandronate sodium(138844-81-2)

Safety Data

• WGK Germany: 3
• RTECS: SZ8563300
• Hazardous Substances Data: 138844-81-2(Hazardous Substances Data)

Usage

Description

Ibandronate sodium, also known as BONIVA, is a nitrogen-containing bisphosphonate that serves as an inhibitor of osteoclast-mediated bone resorption. It is a white-to off-white powder with the chemical name 3-(N-methyl-N-pentyl) amino-1-hydroxypropane-1,1-diphosphonic acid, monosodium salt, monohydrate. Ibandronate sodium has a molecular formula of C9H22NO7P2Na?H20, a molecular weight of 359.24, and is freely soluble in water but practically insoluble in organic solvents.

Uses

Used in Pharmaceutical Industry:
Ibandronate sodium is used as a medication for the treatment and prevention of osteoporosis, a condition characterized by reduced bone mass and increased susceptibility to fractures. It works by inhibiting osteoclast activity, thus reducing bone resorption and maintaining bone density.
Used in Research Applications:
Ibandronate sodium is used as a research tool to study its effects on the proliferation and ultrastructure of Leishmania and Giardia parasites. It helps in generating concentration curves to understand the compound's impact on these organisms.
Additionally, Ibandronate sodium is used to elucidate the route by which nitrogen-containing bisphosphonates (N-BPs) enter the cytosol and inhibit their molecular target. This information is crucial for understanding the mechanism of action of these compounds and their potential applications in various diseases.

Biochem/physiol Actions

Ibandronate sodium inhibits farnesyl diphosphate synthase (IC50 = 20 nM). Ibandronate sodium is also a bone resorption inhibitor. It has been investigated for in vitro anti-tumor effects, such as apoptosis induction, inhibitor of cell growth, inhibition of invasive behavior, and inhibition of angiogenesis and for its in vivo role in various cancers including breast and prostate cancers.

Pharmacokinetics

Its mechanism of action is identical to the other bisphosphonate agents. Administered daily (2.5 mg), ibandronate has been clinically shown to reduce the risk of vertebral fractures by 62%. If administered on an intermittent basis (20 mg), it reduces the risk of vertebral fractures by 50%. Ibandronate (2.5 mg daily), along with 500 mg of supplemental calcium, has been clinically shown to increase BMD in the hip (1.8%), femoral neck (2.0%), and lumbar spine (3.1%). The 150-mg formulation approved in March 2005 represents the first oral therapy for a chronic disease to be administered once monthly.

Clinical Use

Ibandronate sodium was approved in May 2003 for the treatment and prevention of osteoporosis in postmenopausal women.

Side effects

Adverse events as sociated with the injectable form ulation included arthralgia, back and abdominal pain, and hypertens ion. There is a risk of renal toxicity that is inversely related to the rate of administration of this formulation.

Metabolism

The oral bioavailability of this agent is extremely poor (0.6%) and is adversely affected by the presence of food, beverages other than water, and other medications, including calcium or vitamin D supplements and antacids. Because of the increased calcium content in mineral water, patients should not take this medication with this type of water. Drugs that inhibit gastric acid secretion (e.g., H2 antagonists and proton-pump inhibitors) actually promote ibandronate absorption. Like the others in this therapeutic class, ibandronate is not metabolized, and that which is not bound to the bone (40–50% of the absorbed dose) is eliminated renally unchanged. It does not inhibit the cytochrome P450 (CYP450) isozymes. This agent does not require any dosage adjustment for patients with hepatic impairment or mild to moderate renal impairment (creatinine clearance, >30 mL/min). Ibandronate should not be prescribed for patients with severe renal impairment (creatinine clearance, <30 mL/min).

InChI:InChI=1/C9H23NO7P2.Na/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);/q;+1/p-1

Upstream product

• 114084-78-5 ibandronic acid 

Relevant articles and documents

SOLID AND CRYSTALLINE IBANDRONIC ACID

Provided are novel crystalline and amorphous forms of ibandronic acid, methods for their preparation, and pharmaceutical compositions containing them. Also provided are methods for purifying and assaying ibandronic acid in any crystalline form (or amorphous).